365 related articles for article (PubMed ID: 15645737)
1. [Comparison of intravenous ascorbic acid versus intravenous iron for functional iron deficiency in hemodialysis patients].
Ogi M; Horiuchi T; Abe R; Wakabayashi M; Wakabayashi T
Nihon Jinzo Gakkai Shi; 2004; 46(8):804-9. PubMed ID: 15645737
[TBL] [Abstract][Full Text] [Related]
2. Intravenous ascorbic acid in hemodialysis patients with functional iron deficiency: a clinical trial.
Giancaspro V; Nuzziello M; Pallotta G; Sacchetti A; Petrarulo F
J Nephrol; 2000; 13(6):444-9. PubMed ID: 11132761
[TBL] [Abstract][Full Text] [Related]
3. [Iron replacement in hemodialysis patients with a normal serum ferritin level].
Riedel MK; Morgenstern T
Dtsch Med Wochenschr; 2004 Sep; 129(36):1849-53. PubMed ID: 15368155
[TBL] [Abstract][Full Text] [Related]
4. Optimal Serum Ferritin Levels for Iron Deficiency Anemia during Oral Iron Therapy (OIT) in Japanese Hemodialysis Patients with Minor Inflammation and Benefit of Intravenous Iron Therapy for OIT-Nonresponders.
Takasawa K; Takaeda C; Wada T; Ueda N
Nutrients; 2018 Mar; 10(4):. PubMed ID: 29596361
[No Abstract] [Full Text] [Related]
5. Iron supplementation in haemodialysis--practical clinical guidelines.
Silva J; Andrade S; Ventura H; Santos JP; Colaço S; Oliveira C; Ponce P
Nephrol Dial Transplant; 1998 Oct; 13(10):2572-7. PubMed ID: 9794562
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of a low-dose intravenous iron sucrose regimen in peritoneal dialysis patients.
Dittrich E; Schillinger M; Sunder-Plassmann G; Hörl WH; Vychytil A
Perit Dial Int; 2002; 22(1):60-6. PubMed ID: 11929146
[TBL] [Abstract][Full Text] [Related]
7. Effect of intravenous ascorbic acid in hemodialysis patients with EPO-hyporesponsive anemia and hyperferritinemia.
Attallah N; Osman-Malik Y; Frinak S; Besarab A
Am J Kidney Dis; 2006 Apr; 47(4):644-54. PubMed ID: 16564942
[TBL] [Abstract][Full Text] [Related]
8. Intravenous ascorbic acid as an adjuvant therapy for recombinant erythropoietin in hemodialysis patients with hyperferritinemia.
Tarng DC; Wei YH; Huang TP; Kuo BI; Yang WC
Kidney Int; 1999 Jun; 55(6):2477-86. PubMed ID: 10354297
[TBL] [Abstract][Full Text] [Related]
9. Regular low-dose intravenous iron therapy improves response to erythropoietin in haemodialysis patients.
Taylor JE; Peat N; Porter C; Morgan AG
Nephrol Dial Transplant; 1996 Jun; 11(6):1079-83. PubMed ID: 8671972
[TBL] [Abstract][Full Text] [Related]
10. Ferric gluconate is highly efficacious in anemic hemodialysis patients with high serum ferritin and low transferrin saturation: results of the Dialysis Patients' Response to IV Iron with Elevated Ferritin (DRIVE) Study.
Coyne DW; Kapoian T; Suki W; Singh AK; Moran JE; Dahl NV; Rizkala AR;
J Am Soc Nephrol; 2007 Mar; 18(3):975-84. PubMed ID: 17267740
[TBL] [Abstract][Full Text] [Related]
11. Low dose intravenous ascorbic acid for erythropoietin-hyporesponsive anemia in diabetic hemodialysis patients with iron overload.
Lin CL; Hsu PY; Yang HY; Huang CC
Ren Fail; 2003 May; 25(3):445-53. PubMed ID: 12803508
[TBL] [Abstract][Full Text] [Related]
12. The Ferumoxytol for Anemia of CKD Trial (FACT)-a randomized controlled trial of repeated doses of ferumoxytol or iron sucrose in patients on hemodialysis: background and rationale.
Macdougall IC; Dahl NV; Bernard K; Li Z; Batycky A; Strauss WE
BMC Nephrol; 2017 Apr; 18(1):117. PubMed ID: 28372549
[TBL] [Abstract][Full Text] [Related]
13. Intravenous iron supplementation for the treatment of the anemia of moderate to severe chronic renal failure patients not receiving dialysis.
Silverberg DS; Iaina A; Peer G; Kaplan E; Levi BA; Frank N; Steinbruch S; Blum M
Am J Kidney Dis; 1996 Feb; 27(2):234-8. PubMed ID: 8659499
[TBL] [Abstract][Full Text] [Related]
14. The importance of iron in long-term survival of maintenance hemodialysis patients treated with epoetin-alfa and intravenous iron: analysis of 9.5 years of prospectively collected data.
Pollak VE; Lorch JA; Shukla R; Satwah S
BMC Nephrol; 2009 Feb; 10():6. PubMed ID: 19245700
[TBL] [Abstract][Full Text] [Related]
15. Very low doses of direct intravenous iron in each session as maintenance therapy in hemodialysis patients.
Deira J; González-Sanchidrián S; Polanco S; Cebrián C; Jiménez M; Marín J; Gómez-Martino JR; Fernández-Pereira L; Tabernero J
Ren Fail; 2016 Aug; 38(7):1076-81. PubMed ID: 27197731
[TBL] [Abstract][Full Text] [Related]
16. Effect of ascorbic acid administration in hemodialysis patients on in vitro oxidative stress parameters: influence of serum ferritin levels.
Chen WT; Lin YF; Yu FC; Kao WY; Huang WH; Yan HC
Am J Kidney Dis; 2003 Jul; 42(1):158-66. PubMed ID: 12830468
[TBL] [Abstract][Full Text] [Related]
17. Influence of intravenous iron therapy on novel markers of iron deficiency.
Chinnappa S; Bhandari S
Int J Artif Organs; 2010 May; 33(5):297-301. PubMed ID: 20593351
[TBL] [Abstract][Full Text] [Related]
18. [Evaluation of the efficacy of intravenous iron III-hydroxide saccharate for treating adult patients with iron deficiency anemia].
Cançado RD; Brasil SA; Noronha TG; Chiattone CS
Rev Assoc Med Bras (1992); 2005; 51(6):323-8. PubMed ID: 16444338
[TBL] [Abstract][Full Text] [Related]
19. Comparative study of intravenous ascorbic acid versus low-dose desferroxamine in patients on hemodialysis with hyperferritinemia.
Deira J; Diego J; Martínez R; Oyarbide A; González A; Díaz H; Grande J
J Nephrol; 2003; 16(5):703-9. PubMed ID: 14733417
[TBL] [Abstract][Full Text] [Related]
20. Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial.
Nissenson AR; Lindsay RM; Swan S; Seligman P; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):471-82. PubMed ID: 10070911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]